Imunon, Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
Imunon, Inc. (IMNN) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $3.30 million as of 2020-03-31, per its 10-Q filed 2020-05-15.
Discontinued › Notes › Investments › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2020-05-15
- 2020-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $3.30M.
- 2019-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $1.31M.
- 2019-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $1.31M.
- 2019-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $2.31M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2020-03-31 | $3.30M 10-Q · filed 2020-05-15 |
| 2019-09-30 | $1.31M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $1.31M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $2.31M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $6.74M 10-K · filed 2020-03-25 |
| 2018-09-30 | $7.73M 10-Q · filed 2018-11-14 |
| 2018-06-30 | $8.46M 10-Q · filed 2018-08-14 |
| 2018-03-31 | $16.17M 10-Q · filed 2018-05-11 |
| 2017-12-31 | $11.98M 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |